Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

NCT01127841 is registered in ClinicalTrials.gov with Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas as lead sponsor.

NCT NCT01127841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01127841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.
Lead sponsor
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2009
Completion date
December 31, 2015
Enrollment
60 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

follicular non-hodgking´s lymphoma refractory or relapsed after treatment with r-chemotherapy in first line.